Official reprint from UpToDate® www.uptodate.com
©2012 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2012 UpToDate, Inc.
Bacterial vaginosis
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Mar 2012. | This topic last updated: Mar 26, 2012.

INTRODUCTION — Bacterial vaginosis (BV) is the most common cause of vaginal discharge in women of childbearing age, accounting for 40 to 50 percent of cases [1-3]. In the United States, the National Health and Nutrition Examination Survey, which included results from self-collected vaginal swabs from over 3700 women, estimated the prevalence of BV was 29 percent in the general population of women aged 14 to 49 years and 50 percent in African-American women [4]. BV is also common worldwide among women of reproductive age, with variations according to the population studied.

The absence of inflammation is the basis of the term "vaginosis" rather than "vaginitis."

PATHOGENESIS AND MICROBIOLOGY — BV represents a complex change in the vaginal flora characterized by a reduction in concentration of the normally dominant hydrogen-peroxide producing lactobacilli and an increase in concentration of other organisms, especially anaerobic gram negative rods [5-8]. The major bacteria detected are Gardnerella vaginalis, Prevotella species, Porphyromonas species, Bacteroides species, Peptostreptococcus species, Mycoplasma hominis, Ureaplasma urealyticum, and Mobiluncus species [5]. Fusobacterium species and Atopobium vaginae are also common. The mechanism by which the floral imbalance occurs and the role of sexual activity in the pathogenesis of BV are not clear.

Hydrogen-peroxide producing lactobacilli appear to be important in preventing overgrowth of the anaerobes normally present in the vaginal flora. With the loss of lactobacilli, pH rises and massive overgrowth of vaginal anaerobes occurs. These anaerobes produce large amounts of proteolytic carboxylase enzymes, which break down vaginal peptides into a variety of amines that are volatile, malodorous, and associated with increased vaginal transudation and squamous epithelial cell exfoliation, resulting in the typical clinical features observed in patients with BV. (See 'Clinical features' below.). The rise in pH also facilitates adherence of G. vaginalis to the exfoliating epithelial cells.

The difference in vaginal flora between women with and without BV was illustrated in a study that used broad range DNA probes to determine the vaginal flora of 27 women with BV and 46 controls [9]. Overall, 35 bacterial phylotypes were identified in women with BV, including 16 which were newly recognized. Women with BV had a mean of 12.6 phylotypes (range 9 to 17) per sample compared to 3.3 phylotypes (range 1 to 6) per sample in women without BV. The organisms newly identified by PCR include fastidious bacteria termed “BV associated bacterium (BVAB) 1, 2 and 3” in the Clostridiales order, which appear to be specific indicators of BV [10].

Some data suggest that G. vaginalis is the key player in the pathogenesis of BV and the development of a biofilm may be an essential component of this process, in addition to the gradual overgrowth of resident anaerobic vaginal flora. A study of microbiota on the epithelial surfaces of vaginal biopsy specimens from women with BV showed that a biofilm adhered to part or all of the epithelium, and Gardnerella vaginalis comprised 90 percent of bacteria in the biofilm, while Atopobium vaginae accounted for most of the remainder [11]. Subsequent desquamation of these epithelial cells would result in the classic clue cells diagnostic of the disorder. (See 'Diagnosis' below.) In contrast to BV, adherent biofilms were not observed on the epithelium of most healthy controls; instead, unstructured accumulations of bacteria within secretions were loosely attached to specimen surfaces.

RISK FACTORS — Sexual activity is a risk factor for BV, and most experts believe that BV does not occur in women who have never had vaginal intercourse [12,13]. Epidemiologic studies are strongly supportive of sexual transmission of BV pathogens. There is a high occurrence of BV and concordance of flora in women who have sex with women, further suggesting sexual transmission is important in this setting [14-16]. It is not clear, however, whether one type of sexual activity may be more important in the pathogenesis of infection than another. As an example, oral-genital sex may be a more important risk factor than penile intromission into the vagina. (See "Medical care of women who have sex with women".)

Among sexually active women, additional risk factors for acquisition of BV include multiple or new sexual partners, douching, and cigarette smoking [1,2,17-21]. Douching, but not other personal hygienic behaviors, appears to be casually associated with BV [22].

Although some degree of genetic susceptibility to BV is likely, no association between a gene polymorphism and BV has been established [23].

CLINICAL FEATURES — Approximately 50 to 75 percent of women with BV are asymptomatic [12,24,25]. Those with symptoms present with an unpleasant, "fishy smelling" discharge that is more noticeable after coitus. The discharge is off-white, thin, and homogeneous.

Dysuria and dyspareunia rarely occur, while pruritus and vaginal inflammation (erythema, edema) are typically absent. BV can be associated with cervicitis (endocervical mucopurulent discharge or easily induced bleeding), with or without concomitant chlamydial or gonococcal infection [26]. (See "Acute cervicitis".)

DIAGNOSIS — The general diagnostic approach to women with vaginal discharge is reviewed separately. (See "Evaluation of women with symptoms of vaginitis".)

Using microscopy — The diagnosis of BV is based on the presence of characteristic clinical findings and results from laboratory testing; criteria have been established that are simple and useful in office practice where microscopy is available [24]. Three of the four criteria (ie, Amsel criteria) listed below are necessary for diagnosis, although the first three findings are sometimes present in patients with trichomoniasis (table 1).

  • Homogeneous, thin, grayish-white discharge that smoothly coats the vaginal walls
  • Vaginal pH greater than 4.5
  • Positive whiff-amine test, defined as the presence of a fishy odor when 10 percent potassium hydroxide (KOH) is added to a sample of vaginal discharge
  • Clue cells on saline wet mount

The presence of clue cells diagnosed by experienced microscopists is the single most reliable predictor of BV [27]. Clue cells are vaginal epithelial cells studded with adherent coccobacilli that are best appreciated at the edge of the cell (picture 1A-B). In women with BV, at least 20 percent of the epithelial cells on wet mount should be clue cells.

Gram’s stain of vaginal secretions is a reliable method for the diagnosis of BV (figure 1A-B and table 2) [28], but is mostly performed in research studies because it is more cumbersome to use in clinical practice than Amsel criteria [29-31]. Using Gram’s stain as the standard for diagnosing BV, the sensitivity of Amsel criteria for diagnosis of BV is over 90 percent and specificity is 77 percent [32]. If clinical criteria are used to define infection, then the sensitivity reported for Gram’s stain ranges from 62 to 100 percent [33].

The Papanicolaou smear is not reliable for diagnosis of BV (sensitivity 49 percent, specificity 93 percent) [34]. There is no information on the sensitivity and specificity of liquid based methods. If the cytology smear suggests BV (ie, shift in flora from predominantly lactobacilli to predominantly coccobacilli with or without clue cells), women should undergo standard diagnostic testing (vaginal examination, vaginal pH, whiff-amine test, wet mount) and treatment, if appropriate.

Without microscopy — Vaginal culture has no role in diagnosis because there are no bacteria that are diagnostic of BV. Although cultures for G. vaginalis are positive in almost all women with symptomatic infection, the organism is detected in up to 50 to 60 percent of healthy asymptomatic women; thus, its presence alone is not diagnostic.

DNA probes for G. vaginalis are expensive and suffer from the same limitation as culture, but provide fairly quick results and may be useful to practitioners unable to perform microscopy. In one study, for example, the combination of a positive DNA probe (concentration of G. vaginalis ≥107 CFU/mL) and vaginal pH >4.5 had a sensitivity and specificity of 95 and 99 percent, respectively, for diagnosis of BV when clinical criteria were used as the diagnostic standard [35]. Not all studies have reproduced these encouraging results, and over-diagnosis is possible.

Diagnostic cards (eg, Femcard, QuickVue, Pip Activity TestCard) are rapid tests for confirming the clinical suspicion of BV. These cards are particularly useful for practitioners not able to perform microscopy. One group reported these tests detected the presence of elevated vaginal pH and increased amines with sensitivity and specificity of 87 and 92 percent, respectively [36], although others have reported lower values [37].

PCR-based tests are being investigated for molecular diagnosis of BV, mostly based upon molecular quantification of G. vaginalis and Atopobium vaginae [38]. These tests are expensive and of questionable advantage [39].

Differential diagnosis — BV is usually suspected because of high vaginal pH (>4.5). Other causes of increased pH include trichomoniasis, atrophic vaginitis, and desquamative inflammatory vaginitis. These four entities are easily distinguishable by clinical and microscopy features.

  • Women with BV do not have dyspareunia or signs of vaginal inflammation; in contrast, women with atrophic vaginitis, desquamative inflammatory vaginitis, and trichomoniasis usually have these signs and symptoms.
  • Both atrophic vaginitis and desquamative inflammatory vaginitis are associated with an increased number of parabasal cells on microscopy, which is not observed in women with BV.
  • A large number of polymorphonuclear leukocytes on microscopy are characteristic of desquamative inflammatory vaginitis, trichomoniasis, and atrophic vaginitis with infection, but not BV.
  • Visualization of trichomonads readily makes the diagnosis of trichomoniasis in the setting of an elevated pH, however, in other cases we suggest using more sensitive and specific diagnostic tests to diagnose or exclude trichomoniasis.

CONSEQUENCES

  • Pregnant women with BV are at higher risk of preterm delivery (see 'Pregnant women' below) [40-43].
  • There is a causal relationship between BV and [44-46]:

  • Endometrial bacterial colonization
  • Plasma-cell endometritis
  • Postpartum fever
  • Post-hysterectomy vaginal cuff cellulitis
  • Postabortal infection.

  • BV is a risk factor for HIV acquisition and transmission [47,48].

    BV is a risk factor for acquisition of HSV-2, gonorrhea, and chlamydial infection [49,50].

    BV is more common among women with pelvic inflammatory disease (PID), but it is not clear if it is an independent risk factor for this disease [51-53]. In the largest series, diagnosis of BV based on Gram’s stain did not show a strong, independent correlation with development of PID [52], but microbiology on the same patients indicated heavy growth of BV-associated microorganisms increased PID risk (OR 2.03, 95% CI 1.16-3.53) [53].

    It has been hypothesized that the increased risk of acquisition of sexually transmitted infections may be due to lack of hydrogen peroxide–producing lactobacilli in the vaginal flora of women with BV; other factors associated with BV infection, such as local cytokine production, may also play a role.
  • Some studies have found that the presence of G. vaginalis on the cervix, as detected on Papanicolaou smear, is associated with high grade squamous intraepithelial neoplasia (HSIL); however, a causal relationship has not been proven and others have reported no association [54-56].

TREATMENT — BV resolves spontaneously in up to one-third of nonpregnant and one-half of pregnant women [57-60]. Treatment is indicated for relief of symptoms in women with symptomatic infection and to prevent postoperative infection in those with asymptomatic infection prior to abortion or hysterectomy (see 'Gynecologic procedures' below).

Treatment of BV may also reduce the risk of acquiring STDs, including HIV [48,61]. For this reason, some experts support the concept of treating all women with BV regardless of presence or absence of symptoms.

Asymptomatic pregnant women with previous preterm births may also benefit, but screening and treatment of these women is controversial (see 'Pregnant women' below).

Nonpregnant women

Options — Metronidazole or clindamycin administered either orally or intravaginally result in a high rate of clinical cure (70 to 80 percent at four weeks of follow-up) (table 3) [62-65]. Oral medication is more convenient, but associated with a higher rate of systemic side effects, than vaginal administration. Tinidazole is a reasonable oral alternative.

Metronidazole — Metronidazole is the most successful therapy. The oral regimen we recommend is 500 mg twice daily for seven days [66].

There is little evidence of benefit from prolonging therapy greater than seven days. Most comparative studies using multiple divided-dose oral regimens for one week achieved early rates of clinical cure in excess of 90 percent, and cure rates (by Amsel criteria) of approximately 80 percent at four weeks [63,65,67-71]. A randomized trial showed that short-term cure rates were significantly higher when the initial course of metronidazole therapy was 14 days rather than 7 days; however, long-term cure rates (21 days after completion of therapy) were similar for both treatment regimens [20].

Topical vaginal therapy with 0.75 percent metronidazole gel (5 g once daily for five days) is as effective as oral metronidazole [68,69,72]. The choice of oral versus topical therapy depends upon patient preference. The 2 g oral single dose therapy has lower efficacy [73] and is no longer recommended for treatment of BV.

Side effects of metronidazole include a metallic taste, nausea (in 10 percent of patients), transient neutropenia (7.5 percent), a disulfiram-like effect with alcohol, interaction with warfarin, and peripheral neuropathy. Allergy to metronidazole is uncommon; it manifests as rash, urticaria, pruritus, and rarely, anaphylaxis, which can be successfully treated by oral desensitization [74].

Clindamycin — The efficacy of clindamycin has been demonstrated in multiple randomized trials, both comparative and placebo controlled [63,75-78]. Topical vaginal therapy with 2 percent clindamycin cream (5 g of cream containing 100 mg of clindamycin phosphate) is recommended as a seven day regimen, but may be less effective than the metronidazole regimens; nevertheless, topical clindamycin cream is a reasonable therapeutic choice [66].

Alternative regimens include oral clindamycin (300 mg twice daily for seven days) or clindamycin ovules (100 mg intravaginally once daily for three days) [66,79]. A one-day or single application of clindamycin as a bioadhesive is another option (Clindesse). These regimens have not been studied extensively and may have lower efficacy for eradicating BV.

Intravaginal clindamycin therapy has been associated with an increased prevalence of clindamycin resistant anaerobic bacteria in the vagina posttreatment (17 percent of bacterial isolates before versus 53 percent of isolates after therapy) [80]. This effect persisted in most women for at least 90 days after clindamycin treatment. In contrast, increased resistance to metronidazole was not observed in women treated with that drug. Further investigation is required to determine the clinical implications of these findings.

Clindamycin cream should not be used concurrently with latex condoms, which may be weakened.

Pseudomembranous colitis has been reported with both oral and topical clindamycin.

Tinidazole — Tinidazole is a second generation nitroimidazole. It has a longer half-life than metronidazole (12 to 14 hours versus 6 to 7 hours) and fewer side effects [81]. Randomized trials in the United States and elsewhere have shown that it is at least as effective as metronidazole, but not superior [82-86]. If used, we suggest 1 g orally once daily for five days, as efficacy is slightly higher and side effects are slightly less frequent than with shorter course therapy (tinidazole 2 g orally daily for two days) [82].

Less effective and ineffective therapies — Triple-sulfa creams, erythromycin, tetracycline, ampicillin, amoxicillin, acetic acid gel, ascorbic acid, azithromycin, and povidone-iodine vaginal douches are significantly less effective than metronidazole and clindamycin and should not be used [20,87-92]. Cure rates with ampicillin and amoxicillin are mediocre.

Probiotics — Probiotics have been used alone and as adjunctive therapy to antibiotics for treatment of BV and prevention of relapse. Systemic reviews of trials of probiotics for treatment of BV have not found sufficient evidence for or against efficacy [93,94]. Although some trials have reported very promising results, we feel the results should be reproduced in more well-designed and larger trials before use of this therapy is considered. In addition, further investigation is needed to determine the optimum route of administration (oral or vaginal), which strains or combination of strains are most effective (eg, Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC-14, Lactobacillus acidophilus), and the dose and duration of use.

Follow-up — Follow-up is unnecessary if symptoms resolve [66].

Sexual partners — It is not necessary to treat male sexual partners of affected women, as there is no strong evidence that the woman's response to therapy and risk of relapse are influenced by treatment of her male sex partner(s) [66,95]. However, these data are limited and larger trials should be performed.

Sexual intercourse appears to play a role in disease activity. Some studies have reported reduced rates of recurrence when male sexual partners used condoms routinely during coitus or when women remained abstinent [20,96-99].

Women with BV who have sex with women should be encouraged to inform their sexual partner(s) regarding the need for screening, diagnosis, and treatment. (See "Medical care of women who have sex with women".)

Relapse and recurrent infection — Approximately 30 percent of patients with initial responses to therapy have a recurrence of symptoms within three months [67] and more than 50 percent experience a recurrence within 12 months [96]. The explanation for this high rate of recurrence is unclear. Reinfection is possible, but recurrence more likely reflects a failure to eradicate the offending organisms or to reestablish the normal protective vaginal flora dominated by lactobacillus.

We suggest symptomatic relapse be treated initially with a seven-day course of oral or vaginal metronidazole or clindamycin. The treatment regimen may be the same as or different from the initial or previous treatment regimen [66].

After initial induction therapy, most women with a history of recurrent infection benefit from suppressive therapy to maintain an asymptomatic state. We feel any patient with more than three documented episodes of BV in the previous 12 months should be offered a long-term maintenance regimen consisting of maintenance metronidazole gel. Long-term clindamycin regimens, oral or topical, are not advised because of toxicity and lack of documented efficacy. Accordingly, if any of the aforementioned antimicrobials fail, we prescribe metronidazole gel 0.75 percent or an oral nitroimidazole for 7 to 10 days followed by twice weekly dosing of gel for four to six months [66]. In one multicenter prospective trial of this metronidazole gel regimen, recurrent BV occurred in 25.5 percent of patients on suppressive therapy versus 59.1 percent of those receiving placebo [100]. Secondary vaginal candidiasis was a common side effect.

Results can be improved by adding vaginal boric acid to the oral nitroimidazole induction therapy [101]. Metronidazole or tinidazole is taken orally for 7 days; vaginal boric acid 600 mg is begun at the same time and continued for 21 days. Patients are seen for follow-up a day or two after their last boric acid dose; if they are in remission, we immediately begin metronidazole gel twice weekly for four to six months as suppressive therapy. Therapy is then discontinued. Boric acid can cause death if consumed orally; patients should be told to store boric acid in a secure place that is inaccessible to children.

As discussed above, no study has demonstrated reduced rates of recurrence in women whose partners were treated with metronidazole. However, some studies have reported reduced rates of recurrence when sexual partners used condoms routinely with coitus or the patient remained abstinent [20,96-99]. For this reason, some experts suggest these behavioral interventions for women with recurrent infection.

A single trial has reported that use of condoms and combination metronidazole/nystatin ovule therapy may reduce the frequency of recurrent infection [97]. The higher efficacy of the ovule may be due to the higher content of metronidazole (500 mg) compared with the gel (37.5 mg).

Exogenous lactobacillus recolonization with 30 days of oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in addition to 7 days of metronidazole therapy has been suggested, but there is minimal evidence of the efficacy of this approach [65,102]. These results should be reproduced in other trials before use of this therapy is considered.

Vaginal acidifying agents, although popular and widely used, have no role in the treatment of acute or chronic BV, as they have never been shown to enhance cure rates. Douching should be avoided.

Asymptomatic infection — Treatment of asymptomatic BV is typically avoided since patients often spontaneously improve over a period of several months and any antibacterial therapy is often followed by symptomatic vaginal yeast infection. This practice is supported by a double-blind, placebo controlled trial of 54 women with asymptomatic BV who were randomly assigned to receive intravaginal metronidazole or placebo gel [59]. There was no difference in the proportion of women in either group who noticed improvement in vaginal odor or discharge. In addition, 6 of 28 women receiving metronidazole developed symptomatic vaginal candidiasis compared with no women taking placebo.

However, some experts now recommend treatment of asymptomatic BV because affected women are more susceptible to acquiring other STDs (including HIV and increased expression of herpes simplex virus).

Treatment is indicated for asymptomatic women who are scheduled for certain gynecologic procedures (see below). Treatment of asymptomatic infection in pregnant women is more complex and is discussed in detail below (see 'Pregnant women' below).

Gynecologic procedures — Evidence linking asymptomatic BV with gynecologic complications has caused this issue to be reassessed, especially with the availability of topical therapy. It is reasonable to treat asymptomatic BV prior to hysterectomy and before pregnancy termination to prevent postprocedure infection (cuff infection after hysterectomy, endometritis after abortion). Reported reductions in postoperative infectious complications range from 10 to 75 percent [103-109].

Pregnant women

Symptomatic BV infection — All women with symptomatic BV should be treated to relieve bothersome symptoms. Oral treatment is effective and has not been associated with adverse fetal or obstetrical effects [110-115]. The therapeutic options include [66]:

Some clinicians avoid use of metronidazole in the first trimester because it crosses the placenta, and thus has a potential for teratogenicity. However, meta-analysis has not found any relationship between metronidazole exposure during the first trimester of pregnancy and birth defects [116] and the Centers for Disease Control and Prevention no longer discourage the use of metronidazole in the first trimester [117]. An additional concern is that the drug is mutagenic in bacteria and carcinogenic in mice, but there is no evidence of harm in humans.

As mentioned above, topical therapy is as effective as oral therapy in the treatment of nonpregnant women with BV. In contrast, some experts avoid topical therapy in pregnant women because they believe oral treatment is more effective against potential subclinical upper genital tract infection [118-120].

Asymptomatic BV infection — As many as one-third of pregnant women in the United States have BV [40]. Of concern, a meta-analysis has reported a statistically significant increased risk of preterm birth in these women; the pooled odds ratio for prematurity was 2.19 (95% CI, 1.54-3.12) [121]. The increased risk of preterm birth attributable to BV appears to be linked to preterm labor due to chorioamnionitis [41,122]. Other complications of BV are endometritis after cesarean delivery (55 versus 17 percent in uninfected controls) [123] and after vaginal birth (8 versus 1.5 percent in uninfected controls), and possibly an increased risk of miscarriage [121,124].

Despite the association between BV and preterm birth, screening and treatment of asymptomatic BV during pregnancy is controversial. Meta-analyses of randomized trials performed in general obstetric populations have not consistently found that treatment of asymptomatic infection reduces the incidence of preterm labor or delivery [110,125], but this may not apply to women at high risk for preterm birth or those treated early in pregnancy.

  • A Cochrane meta-analysis included 15 trials involving 5888 pregnant women asymptomatic for BV and at average risk of preterm birth (a mixed population of women at low and high risk for preterm delivery) [110]. Antibiotic therapy was highly effective in eradicating infection, but did not significantly reduce the odds of preterm birth at less than 37 weeks (OR 0.91, 95% CI 0.78-1.06) or the risk of preterm premature rupture of membranes (OR 0.88, 95% CI 0.61-1.28).

    However, treatment initiated before 20 weeks of gestation appeared to reduce the risk of preterm birth before 37 weeks (OR 0.63, 95% CI 0.48-0.84; five trials, 2387 women).

    When the Cochrane reviewers separately analyzed the subgroup of women with a history of one or more prior preterm births (ie, women at high risk for preterm birth), the detection and treatment of asymptomatic BV appeared to markedly reduce the rate of preterm prelabor rupture of membranes (OR 0.14, 95% CI 0.05-0.38) and low birthweight (OR 0.31, 95% CI 0.13-0.75; two trials, 114 women), but the reduction in risk of subsequent preterm birth was not statistically significant (OR 0.83, 95% CI 0.59-1.17; five trials, 622 women) [110]. The lack of significant reduction in preterm birth was largely due to data from the largest (n = 1953) trial of screening and treatment of BV in pregnant women, which reported an absence of benefit of metronidazole treatment in both average risk women and in the subgroup of women at high risk of preterm birth (n = 210) [126].
  • The United States Preventive Services Task Force (USPSTF) also evaluated the effect of treatment of asymptomatic BV in women at high risk for preterm birth [125]. Due to heterogeneity, results could not be pooled. Three trials showed fewer deliveries before 37 weeks of gestation with treatment, one showed no benefit, and one trial [127] reported an increase in preterm deliveries after treatment with metronidazole. For delivery before 34 weeks of gestation, meta-analysis was possible and showed no significant treatment benefit.
  • In a meta-analysis of five randomized trials of asymptomatic women with BV at <22 weeks of gestation treated with clindamycin or placebo/no treatment, clindamycin therapy was associated with a reduction in preterm birth <37 weeks (3.7 percent [44/1183] versus 6.2 percent [72/1163]; fixed effects RR 0.60, 95% CI 0.42-0.86 random effects 0.64, 95% CI 0.39-1.05) and late miscarriage (0.3 percent [2/639] versus 1.9 percent [12/631]; RR 0.20, 95%CI 0.05-0.76) [128]. Subgroup analysis revealed that oral, not vaginal, clindamycin therapy was associated with a significant reduction in preterm birth (oral therapy RR 0.39, 95% CI 0.20-0.76; vaginal RR 0.73, 95% CI 0.47-1.14). The analysis included a mixed population of women at both low and high risk of preterm birth.

Based upon these data, routinely screening and treating all pregnant women with asymptomatic BV to prevent preterm birth and its consequences is not recommended. It is not possible to define specific features characterizing a subgroup of women who might respond favorably to a screening and treatment protocol. Defining these features is an active area of investigation.

As illustrated above, there may be benefits to early screening and treatment of asymptomatic pregnant women who have a history of a previous preterm delivery, but there are insufficient data to recommend this as a routine practice [112,121,129-131]. Further definition of high risk subgroups is under investigation. As an example, women with polymorphisms of genes regulating cytokine production (eg, tumor necrosis factor variants) have a greater proinflammatory immune response to infectious stimuli, such as BV [132]. Enhanced induction of cytokines in these women could then lead to preterm labor or rupture of membranes. Other aspects of host response (eg, low levels of IgA to Gardnerella vaginalis) or the specific types of BV associated bacteria involved (eg, bacteria that produce high levels of sialidase or protease) may also play a role in placing some women with BV at high risk of preterm birth. (See "Risk factors for preterm labor and delivery", section on 'Infection' and "Risk factors for preterm labor and delivery", section on 'Genetic factors'.)

When treatment of BV is initiated, the optimal choice of antibiotic, timing of therapy, duration of use, and harms of therapy are also controversial. The first trials demonstrated a reduction in preterm birth in high risk women treated with oral metronidazole or oral metronidazole and erythromycin (table 4) [118-120]. However, in two studies, metronidazole use in pregnancy appeared to increase the risk of preterm birth [127,133]. This association requires further investigation and confirmation before avoiding metronidazole for treatment of BV in pregnancy. Other trials suggest that oral clindamycin given early in pregnancy is an effective therapy [128] and that topical clindamycin given in the second half of pregnancy is less effective and even associated with an increase in low birth weight and neonatal infection [134]. Therefore, we use oral therapy when treatment is indicated, and consider both metronidazole and clindamycin acceptable choices.

Breastfeeding women — The American Academy of Pediatrics (AAP) considers clindamycin use compatible with breastfeeding [135]. However, clindamycin has the potential to cause adverse effects on the breastfed infant's gastrointestinal flora so the infant should be monitored for diarrhea, candidiasis (thrush, diaper rash) or, rarely, blood in the stool indicating possible antibiotic-associated colitis [136]. Infant side effects are less likely with vaginal than oral use since only about 30 percent of a vaginal dose is absorbed.

The AAP considers use of oral metronidazole and tinidazole of concern in nursing women [135]. There are no human data supporting an association between metronidazole and cancer; however, an association with carcinogenesis in rodents has been demonstrated [137]. Outcomes data of maternal metronidazole use did not show a significant increase in adverse events compared to use of other antimicrobials, although a cohort study found a nonsignificant trend toward more loose stools and more candidal colonization in metronidazole-exposed infants. Since the relative infant dose of metronidazole is high (29 percent) with maternal administration of the 2 g one-time dose, the AAP recommends that mothers receiving this dose express and discard their milk for 24 hours. (See "Principles of medication use during lactation".)

Use of vaginal metronidazole has not been studied during breastfeeding. After vaginal administration, plasma levels are less than 2 percent of those after a 500 mg oral dose, so vaginal use of metronidazole during breastfeeding is unlikely to be of concern [137].

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)

SUMMARY AND RECOMMENDATIONS

  • Bacterial vaginosis (BV) is the most common cause of vaginitis in women of childbearing age. (See 'Introduction' above.)
  • BV represents a complex change in the vaginal flora characterized by a reduction in concentration of the normally dominant hydrogen-peroxide producing lactobacilli and an increase in concentration of other organisms, particularly anaerobes. (See 'Pathogenesis and microbiology' above.)
  • Approximately 50 to 75 percent of women with BV are asymptomatic. Those with symptoms present with an unpleasant, "fishy smelling" discharge that is more noticeable after coitus. The discharge is off-white, thin, and homogeneous. (See 'Clinical features' above.)
  • Sequelae of BV include an increased risk of preterm birth, plasma-cell endometritis, postpartum fever, post-hysterectomy vaginal cuff cellulitis, postabortal infection, pelvic inflammatory disease, and acquisition of other sexually transmitted infections. (See 'Consequences' above.)

Diagnosis

  • The diagnosis of BV is based on clinical findings and laboratory testing. Three of the following four criteria (Amsel criteria) are necessary for diagnosis:

  • Homogeneous, thin, grayish-white discharge that smoothly coats the vaginal walls
  • Vaginal pH greater than 4.5
  • Positive whiff-amine test, defined as the presence of a fishy odor when 10 percent potassium hydroxide (KOH) is added to a sample of vaginal discharge
  • Clue cells on saline wet mount

The presence of clue cells is the single most reliable predictor of BV. Vaginal culture is not useful. (See 'Diagnosis' above.)

Treatment of nonpregnant women

  • Metronidazole 500 mg twice daily orally for seven days
  • Metronidazole gel 0.75 percent (5 g) once daily vaginally for five days
  • Clindamycin 2% vaginal cream once daily at bedtime for seven days
  • Clindamycin 300 mg twice per day orally for seven days
  • Clindamycin 100 mg vaginal suppositories at bedtime for three days
  • Clindamycin bioadhesive cream (Clindesse) 2% as a single vaginal dose of 5 g of cream containing 100 mg of clindamycin phosphate.

  • We suggest treatment of asymptomatic women who are to undergo pregnancy termination or hysterectomy (Grade 2B). Preoperative treatment decreases the frequency of postoperative infectious complications. (See 'Gynecologic procedures' above.)
  • We recommend not treating sexual partners of women with BV (Grade 1B). (See 'Sexual partners' above.)
  • Approximately 30 percent of patients with an initial response to therapy have a recurrence of symptoms within three months and more than 50 percent experience a recurrence within 12 months. We treat symptomatic relapse with a longer course of therapy, using a different antibiotic than that used for the initial episode. For women who prefer preventive therapy instead of treatment of frequent episodes of BV, we suggest metronidazole or tinidazole orally for 7 days; vaginal boric acid 600 mg is begun at the same time and continued for 21 days (Grade 2B). Patients are seen for follow-up a day or two after their last boric acid dose; if they are in remission, we immediately begin metronidazole gel twice weekly for four to six months as suppressive therapy. (See 'Relapse and recurrent infection' above.)

Treatment of pregnant women

  • Pregnant women with BV are at increased risk of preterm birth. We recommend not screening all pregnant women for BV, given there is no evidence that screening and treatment of asymptomatic infection reduces the risk of preterm birth (Grade 1A). There may be benefits to screening and treating asymptomatic pregnant women who have a history of a previous preterm delivery. (See 'Asymptomatic BV infection' above.)
  • We treat pregnant women with symptomatic BV infection to relieve symptoms. We suggest seven days of clindamycin 300 mg orally twice daily or metronidazole 500 mg orally twice daily (Grade 2C). (See 'Symptomatic BV infection' above.)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. Joesoef, M, Schmid, G. Bacterial vaginosis. In: Clinical evidence, BMJ Publishing Group, London 2001. p.887.
  2. Morris M, Nicoll A, Simms I, et al. Bacterial vaginosis: a public health review. BJOG 2001; 108:439.
  3. Tolosa JE, Chaithongwongwatthana S, Daly S, et al. The International Infections in Pregnancy (IIP) study: variations in the prevalence of bacterial vaginosis and distribution of morphotypes in vaginal smears among pregnant women. Am J Obstet Gynecol 2006; 195:1198.
  4. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007; 109:114.
  5. Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993; 169:450.
  6. Ling Z, Kong J, Liu F, et al. Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics 2010; 11:488.
  7. Eschenbach DA, Davick PR, Williams BL, et al. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989; 27:251.
  8. Lamont RF, Sobel JD, Akins RA, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 2011; 118:533.
  9. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353:1899.
  10. Fredricks DN, Fiedler TL, Thomas KK, et al. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007; 45:3270.
  11. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005; 106:1013.
  12. Yen S, Shafer MA, Moncada J, et al. Bacterial vaginosis in sexually experienced and non-sexually experienced young women entering the military. Obstet Gynecol 2003; 102:927.
  13. Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis 2009; 200:1662.
  14. Skinner CJ, Stokes J, Kirlew Y, et al. A case-controlled study of the sexual health needs of lesbians. Genitourin Med 1996; 72:277.
  15. Fethers K, Marks C, Mindel A, Estcourt CS. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex Transm Infect 2000; 76:345.
  16. Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis 2009; 199:680.
  17. Ness RB, Hillier SL, Richter HE, et al. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol 2002; 100:765.
  18. Schwebke JR, Desmond RA, Oh MK. Predictors of bacterial vaginosis in adolescent women who douche. Sex Transm Dis 2004; 31:433.
  19. Ness RB, Kip KE, Soper DE, et al. Variability of bacterial vaginosis over 6- to 12-month intervals. Sex Transm Dis 2006; 33:381.
  20. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007; 44:213.
  21. Brotman RM, Klebanoff MA, Nansel TR, et al. A longitudinal study of vaginal douching and bacterial vaginosis--a marginal structural modeling analysis. Am J Epidemiol 2008; 168:188.
  22. Klebanoff MA, Nansel TR, Brotman RM, et al. Personal hygienic behaviors and bacterial vaginosis. Sex Transm Dis 2010; 37:94.
  23. Verstraelen H, Verhelst R, Nuytinck L, et al. Gene polymorphisms of Toll-like and related recognition receptors in relation to the vaginal carriage of Gardnerella vaginalis and Atopobium vaginae. J Reprod Immunol 2009; 79:163.
  24. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14.
  25. Klebanoff MA, Schwebke JR, Zhang J, et al. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol 2004; 104:267.
  26. Marrazzo JM, Wiesenfeld HC, Murray PJ, et al. Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis 2006; 193:617.
  27. Eschenbach DA, Hillier S, Critchlow C, et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158:819.
  28. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29:297.
  29. Schwebke JR, Hillier SL, Sobel JD, et al. Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol 1996; 88:573.
  30. Tam MT, Yungbluth M, Myles T. Gram stain method shows better sensitivity than clinical criteria for detection of bacterial vaginosis in surveillance of pregnant, low-income women in a clinical setting. Infect Dis Obstet Gynecol 1998; 6:204.
  31. Gratacós E, Figueras F, Barranco M, et al. Prevalence of bacterial vaginosis and correlation of clinical to Gram stain diagnostic criteria in low risk pregnant women. Eur J Epidemiol 1999; 15:913.
  32. Landers DV, Wiesenfeld HC, Heine RP, et al. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol 2004; 190:1004.
  33. Spiegel CA. Bacterial vaginosis. Clin Microbiol Rev 1991; 4:485.
  34. Greene JF 3rd, Kuehl TJ, Allen SR. The papanicolaou smear: inadequate screening test for bacterial vaginosis during pregnancy. Am J Obstet Gynecol 2000; 182:1048.
  35. Sheiness D, Dix K, Watanabe S, Hillier SL. High levels of Gardnerella vaginalis detected with an oligonucleotide probe combined with elevated pH as a diagnostic indicator of bacterial vaginosis. J Clin Microbiol 1992; 30:642.
  36. Hillier, S. Personal communication.
  37. Gutman RE, Peipert JF, Weitzen S, Blume J. Evaluation of clinical methods for diagnosing bacterial vaginosis. Obstet Gynecol 2005; 105:551.
  38. Menard JP, Fenollar F, Henry M, et al. Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis 2008; 47:33.
  39. Dumonceaux TJ, Schellenberg J, Goleski V, et al. Multiplex detection of bacteria associated with normal microbiota and with bacterial vaginosis in vaginal swabs by use of oligonucleotide-coupled fluorescent microspheres. J Clin Microbiol 2009; 47:4067.
  40. Klebanoff MA, Hillier SL, Nugent RP, et al. Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation? Am J Obstet Gynecol 2005; 192:470.
  41. Eschenbach DA. Bacterial vaginosis: emphasis on upper genital tract complications. Obstet Gynecol Clin North Am 1989; 16:593.
  42. Flynn CA, Helwig AL, Meurer LN. Bacterial vaginosis in pregnancy and the risk of prematurity: a meta-analysis. J Fam Pract 1999; 48:885.
  43. Hauth JC, Macpherson C, Carey JC, et al. Early pregnancy threshold vaginal pH and Gram stain scores predictive of subsequent preterm birth in asymptomatic women. Am J Obstet Gynecol 2003; 188:831.
  44. Andrews WW, Hauth JC, Cliver SP, et al. Association of asymptomatic bacterial vaginosis with endometrial microbial colonization and plasma cell endometritis in nonpregnant women. Am J Obstet Gynecol 2006; 195:1611.
  45. Oleen-Burkey MA, Hillier SL. Pregnancy complications associated with bacterial vaginosis and their estimated costs. Infect Dis Obstet Gynecol 1995; 3:149.
  46. MacDermott RI. Bacterial vaginosis. Br J Obstet Gynaecol 1995; 102:92.
  47. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863.
  48. Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis 2005; 192:1372.
  49. Cherpes TL, Meyn LA, Krohn MA, et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003; 37:319.
  50. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003; 36:663.
  51. Soper DE, Brockwell NJ, Dalton HP, Johnson D. Observations concerning the microbial etiology of acute salpingitis. Am J Obstet Gynecol 1994; 170:1008.
  52. Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004; 104:761.
  53. Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005; 162:585.
  54. Klomp JM, Boon ME, Van Haaften M, Heintz AP. Cytologically diagnosed Gardnerella vaginalis infection and cervical (pre)neoplasia as established in population-based cervical screening. Am J Obstet Gynecol 2008; 199:480.e1.
  55. Boyle DC, Barton SE, Uthayakumar S, et al. Is bacterial vaginosis associated with cervical intraepithelial neoplasia? Int J Gynecol Cancer 2003; 13:159.
  56. Discacciati MG, Simoes JA, Lopes ES, et al. Is bacterial vaginosis associated with squamous intraepithelial lesion of the uterine cervix? Diagn Cytopathol 2006; 34:323.
  57. Klebanoff MA, Hauth JC, MacPherson CA, et al. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. Am J Obstet Gynecol 2004; 190:363.
  58. Hay PE, Morgan DJ, Ison CA, et al. A longitudinal study of bacterial vaginosis during pregnancy. Br J Obstet Gynaecol 1994; 101:1048.
  59. Schwebke JR. Asymptomatic bacterial vaginosis: response to therapy. Am J Obstet Gynecol 2000; 183:1434.
  60. Hillier SL, Lipinski C, Briselden AM, Eschenbach DA. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet Gynecol 1993; 81:963.
  61. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 2007; 196:517.e1.
  62. National guideline for the management of bacterial vaginosis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S16.
  63. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999; 28 Suppl 1:S57.
  64. Greaves WL, Chungafung J, Morris B, et al. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1988; 72:799.
  65. Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009; :CD006055.
  66. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.
  67. Hillier, S, Holmes, KK. Bacterial vaginosis. In: Holmes, KK, Mardh, PA, Sparling, PF, Wiesner, PJ (Eds), Sexually Transmitted Diseases, 2nd ed, McGraw-Hill, New York: 1990, p. 547.
  68. Ferris DG, Litaker MS, Woodward L, et al. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995; 41:443.
  69. Hanson JM, McGregor JA, Hillier SL, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J Reprod Med 2000; 45:889.
  70. Joesoef MR, Schmid GP. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1995; 20 Suppl 1:S72.
  71. Bro F. Metronidazole pessaries compared with placebo in the treatment of bacterial vaginosis. Scand J Prim Health Care 1990; 8:219.
  72. Livengood CH 3rd, Soper DE, Sheehan KL, et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis 1999; 26:137.
  73. Swedberg J, Steiner JF, Deiss F, et al. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. JAMA 1985; 254:1046.
  74. Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 1991; 88:279.
  75. Faro S, Skokos CK, Clindesse Investigators Group. The efficacy and safety of a single dose of Clindesse vaginal cream versus a seven-dose regimen of Cleocin vaginal cream in patients with bacterial vaginosis. Infect Dis Obstet Gynecol 2005; 13:155.
  76. Ahmed-Jushuf IH, Shahmanesh M, Arya OP. The treatment of bacterial vaginosis with a 3 day course of 2% clindamycin cream: results of a multicentre, double blind, placebo controlled trial. B V Investigators Group. Genitourin Med 1995; 71:254.
  77. Hillier S, Krohn MA, Watts DH, et al. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. Obstet Gynecol 1990; 76:407.
  78. Livengood CH 3rd, Thomason JL, Hill GB. Bacterial vaginosis: treatment with topical intravaginal clindamycin phosphate. Obstet Gynecol 1990; 76:118.
  79. Paavonen J, Mangioni C, Martin MA, Wajszczuk CP. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol 2000; 96:256.
  80. Beigi RH, Austin MN, Meyn LA, et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004; 191:1124.
  81. Tinidazole (Tindamax)--a new option for treatment of bacterial vaginosis. Med Lett Drugs Ther 2007; 49:73.
  82. Ekgren J, Norling BK, Degre M, Midtvedt T. Comparison of tinidazole given as a single dose and on 2 consecutive days for the treatment of nonspecific bacterial vaginosis. Gynecol Obstet Invest 1988; 26:313.
  83. Livengood CH 3rd, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2007; 110:302.
  84. Schindler EM, Thamm H, Ansmann EB, et al. [Treatment of bacterial vaginitis. Multicenter, randomized, open study with tinidazole in comparison with metronidazole]. Fortschr Med 1991; 109:138.
  85. Prakash AT, Sharma LK, Pandit PN. Primary carcinoma of the gallbladder. Br J Surg 1975; 62:33.
  86. Schwebke JR, Desmond RA. Tinidazole vs metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol 2011; 204:211.e1.
  87. McCormack WM, Covino JM, Thomason JL, et al. Comparison of clindamycin phosphate vaginal cream with triple sulfonamide vaginal cream in the treatment of bacterial vaginosis. Sex Transm Dis 2001; 28:569.
  88. Wathne B, Holst E, Hovelius B, Mårdh PA. Erythromycin versus metronidazole in the treatment of bacterial vaginosis. Acta Obstet Gynecol Scand 1993; 72:470.
  89. Piot P. Bacterial vaginosis. An evaluation of treatment. Scand J Urol Nephrol Suppl 1984; 86:229.
  90. Wewalka G, Stary A, Bosse B, et al. Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis. Dermatology 2002; 204 Suppl 1:79.
  91. Duff P, Lee ML, Hillier SL, et al. Amoxicillin treatment of bacterial vaginosis during pregnancy. Obstet Gynecol 1991; 77:431.
  92. Schoeman J, Steyn PS, Odendaal HJ, Grové D. Bacterial vaginosis diagnosed at the first antenatal visit better predicts preterm labour than diagnosis later in pregnancy. J Obstet Gynaecol 2005; 25:751.
  93. Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2009; :CD006289.
  94. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect 2007; 13:657.
  95. Potter J. Should sexual partners of women with bacterial vaginosis receive treatment? Br J Gen Pract 1999; 49:913.
  96. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193:1478.
  97. Sanchez S, Garcia PJ, Thomas KK, et al. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 2004; 191:1898.
  98. Schwebke JR, Desmond R. Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseases. Sex Transm Dis 2005; 32:654.
  99. Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect 2004; 80:58.
  100. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006; 194:1283.
  101. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009; 36:732.
  102. Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 2006; 8:1450.
  103. Penney GC, Thomson M, Norman J, et al. A randomised comparison of strategies for reducing infective complications of induced abortion. Br J Obstet Gynaecol 1998; 105:599.
  104. Larsson PG, Platz-Christensen JJ, Dalaker K, et al. Treatment with 2% clindamycin vaginal cream prior to first trimester surgical abortion to reduce signs of postoperative infection: a prospective, double-blinded, placebo-controlled, multicenter study. Acta Obstet Gynecol Scand 2000; 79:390.
  105. Miller L, Thomas K, Hughes JP, et al. Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication. BJOG 2004; 111:982.
  106. Crowley T, Low N, Turner A, et al. Antibiotic prophylaxis to prevent post-abortal upper genital tract infection in women with bacterial vaginosis: randomised controlled trial. BJOG 2001; 108:396.
  107. Larsson PG, Platz-Christensen JJ, Thejls H, et al. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am J Obstet Gynecol 1992; 166:100.
  108. Larsson PG, Carlsson B. Does pre- and postoperative metronidazole treatment lower vaginal cuff infection rate after abdominal hysterectomy among women with bacterial vaginosis? Infect Dis Obstet Gynecol 2002; 10:133.
  109. ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180.
  110. McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2007; :CD000262.
  111. Leitich H, Brunbauer M, Bodner-Adler B, et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol 2003; 188:752.
  112. Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: a systematic review. Obstet Gynecol 2005; 105:857.
  113. Guise JM, Mahon SM, Aickin M, et al. Screening for bacterial vaginosis in pregnancy. Am J Prev Med 2001; 20:62.
  114. Riggs MA, Klebanoff MA. Treatment of vaginal infections to prevent preterm birth: a meta-analysis. Clin Obstet Gynecol 2004; 47:796.
  115. Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol 1995; 173:1527.
  116. Caro-Patón T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44:179.
  117. Centers for Disease Control and Prevention, Workowsk,i KA, Berman, SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55(RR-11):1.
  118. McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol 1997; 104:1391.
  119. Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994; 171:345.
  120. Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995; 333:1732.
  121. Leitich H, Bodner-Adler B, Brunbauer M, et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003; 189:139.
  122. Hillier SL, Martius J, Krohn M, et al. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319:972.
  123. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for post-cesarean endometritis. Obstet Gynecol 1990; 75:52.
  124. Newton ER, Prihoda TJ, Gibbs RS. A clinical and microbiologic analysis of risk factors for puerperal endometritis. Obstet Gynecol 1990; 75:402.
  125. Nygren P, Fu R, Freeman M, et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 148:220.
  126. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000; 342:534.
  127. Odendaal HJ, Popov I, Schoeman J, et al. Preterm labour--is bacterial vaginosis involved? S Afr Med J 2002; 92:231.
  128. Lamont RF, Nhan-Chang CL, Sobel JD, et al. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 205:177.
  129. U.S. Preventive Services Task Force. Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148:214.
  130. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003; 361:983.
  131. Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003; 101:516.
  132. Macones GA, Parry S, Elkousy M, et al. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth. Am J Obstet Gynecol 2004; 190:1504.
  133. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345:487.
  134. Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. Br J Obstet Gynaecol 1999; 106:652.
  135. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.
  136. LactMed available at http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~R2NQWq:1. (Accessed january 19, 2010).
  137. Lactmed. Available at http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~R2NQWq:2. (Accessed January 19, 2010).
Topic 5451 Version 19.0

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.